This article is provided for educational and informational purposes only. All compounds discussed are supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption. Analytical-grade biochemical reference standards are intended exclusively for in-vitro research, analytical method development, identity verification, and laboratory evaluation by qualified research customers.
KLOW Blend is a four-compound research reference standard that combines BPC-157 (10mg), TB-500 (10mg), GHK-Cu (50mg), and KPV (10mg) in a single lyophilized vial. Each of the four constituents has its own distinct research history and its own primary receptor or signaling target. Together, they represent something interesting for laboratory researchers studying tissue repair: three of the four compounds are studied for overlapping regenerative pathways, and the fourth (KPV) engages an entirely separate anti-inflammatory arm.
The blend is not a therapeutic. It is a research reference material. And this article walks through what each of the four compounds actually does at the molecular level, what the peer-reviewed literature says about them, and why researchers might investigate them as a combined system rather than separately.
The story starts in the early 1990s with a Croatian gastroenterologist named Pavle Sikiric, who was studying stomach juice.
KLOW Blend is a proprietary Vitro Labs research reference standard. It combines four separate compounds into a single lyophilized 80mg vial, at fixed masses per component: 10mg of BPC-157, 10mg of TB-500, 50mg of GHK-Cu, and 10mg of KPV. Each of these four compounds has an independent research literature that spans two to four decades of peer-reviewed work.
The rationale for combining them into a single reference material is straightforward from a laboratory perspective. Researchers studying tissue repair pathways in preclinical models often want to evaluate multiple signaling arms in parallel — the 15-amino-acid compound arm (BPC-157), the thymosin arm (TB-500), the copper complex arm (GHK-Cu), and the melanocortin arm (KPV). Having all four in one identity-verified vial simplifies inventory, reduces batch-variability across the study design, and consolidates the Certificate of Analysis into one document.
Before going further, an important framing note.
BPC-157 is a 15-amino-acid 15-amino-acid compound derived from a partial sequence of a protein originally isolated from human gastric juice. The Croatian research group led by Pavle Sikiric at the University of Zagreb first characterized it in the early 1990s, and Sikiric’s team has published more than 100 papers on it since.
BPC-157 does not appear to bind a single, well-characterized receptor the way most drug molecules do. Instead, the literature describes it as a "cytoprotective" compound that seems to nudge a network of signaling proteins at once. Sikiric and colleagues (2013) in Inflammopharmacology reported that BPC-157 modulated at least three distinct pathway systems in rat models of injury: angiogenesis via VEGF signaling, growth-factor receptor expression, and nitric oxide (NO) pathway regulation (PMID: 22950504).
A subsequent paper by Chang and colleagues (2011) in the Journal of Applied Physiology looked specifically at tendon-derived fibroblasts in cell culture and reported that BPC-157 increased the outgrowth of these cells and shifted expression of growth hormone receptor mRNA (PMID: 21030672). That’s the paper most often cited when researchers discuss why BPC-157 shows up so consistently in tendon and ligament repair research.
BPC-157 anchors the tissue-repair arm of the blend. In the combined-pathway research rationale, it’s the compound that hits the broadest range of downstream signaling targets.
TB-500 is a synthetic compound fragment corresponding to a bioactive region of thymosin beta-4 (Tβ4). The parent protein was first isolated from the thymus gland by Allan Goldstein’s group in the early 1980s.
The best-characterized mechanism for Tβ4 (and by extension TB-500) is actin sequestration. Goldstein and colleagues (2005) in the Annals of the New York Academy of Sciences laid out the actin-binding chemistry in detail and described the downstream consequences: cell migration, angiogenesis, and modulation of inflammatory response (PMID: 16110150). When cells need to migrate — for instance, into a wound bed — they need to reorganize their actin cytoskeleton, and Tβ4 sits upstream of that process.
Smart and colleagues (2007) in Nature looked at TB-500 in cardiac tissue repair models and reported that the compound promoted migration of epicardial progenitor cells in mouse hearts (PMID: 17554337). The paper is one of the more mechanistically rigorous in the TB-500 literature and is often cited when the compound is discussed in tissue-regeneration contexts.
TB-500 complements BPC-157 by adding a distinct upstream mechanism (actin cytoskeleton modulation via a well-characterized binding partner) to the same broad research area — tissue repair and cell migration. Researchers studying the two compounds together often frame them as a paired system where BPC-157 covers the growth-factor-receptor arm and TB-500 covers the cell-migration arm.
GHK-Cu is a copper-binding 3-amino-acid compound with the sequence glycyl-L-histidyl-L-lysine, complexed with a copper(II) ion. Loren Pickart first isolated it from human plasma in 1973 while studying age-related changes in plasma protein activity.
The 50mg of GHK-Cu in KLOW is by mass the largest constituent, and its research base is one of the deepest in the copper-compound field. Pickart and Margolina (2015) in the International Journal of Molecular Sciences reviewed the mechanism in detail: GHK-Cu delivers copper to cells, and the copper complex complex has been reported to influence gene expression across a broad range of pathways — wound healing, extracellular matrix remodeling, antioxidant defense, and neurotrophic signaling (PMID: 26264936).
A separate study by Pickart, Vasquez-Soltero, and Margolina (2012) in BioMed Research International looked at gene-expression profiling in cell cultures exposed to GHK-Cu and reported significant modulation of more than 4,000 human genes (PMID: 24707223). The scale of that signal is one reason GHK-Cu keeps showing up in longevity and regenerative-signaling research.
GHK-Cu adds the copper-signaling arm and the extracellular-matrix remodeling arm to the blend. Where BPC-157 and TB-500 operate mainly through compound-compound interactions with signaling machinery, GHK-Cu operates through a metal-cofactor mechanism — copper is the active ingredient, and the 3-amino-acid compound is the delivery vehicle.
KPV is a 3-amino-acid compound: lysine-proline-valine. It corresponds to the C-terminal three amino acids of alpha-melanocyte-stimulating hormone (α-MSH). The full α-MSH molecule is well-studied for its role in pigmentation and inflammation; KPV is the minimal C-terminal fragment that retains the anti-inflammatory activity of the parent hormone.
This is where KLOW diverges from GLOW.
KPV is not primarily a tissue-repair compound. It engages the melanocortin receptor system and appears to attenuate inflammatory signaling. Getting and colleagues (2003) in the Journal of Immunology studied KPV and related C-terminal α-MSH fragments in inflammatory models and reported inhibition of NF-κB signaling and reductions in downstream pro-inflammatory cytokine production (PMID: 12496404).
A more recent paper by Kannengiesser and colleagues (2008) in Inflammatory Bowel Diseases examined KPV specifically in gut inflammation models and reported anti-inflammatory activity in cell culture and in mouse models of colitis (PMID: 18521914). The gut-inflammation research is what has driven most of the recent interest in KPV.
KPV is the anti-inflammatory arm. Its inclusion transforms the blend from a pure tissue-repair reference material (which is essentially what GLOW is — see below) into a combined tissue-repair-plus-anti-inflammation reference material. That’s the whole point of the K in KLOW.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. KLOW Blend and its constituent compounds are research compounds not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for administration in humans or animals outside of approved research protocols. Products are supplied strictly for laboratory research use only.
Why put four compounds into one vial instead of four?
From a research-material perspective, the combined-pathway framing is the honest answer. Three of the four constituents (BPC-157, TB-500, GHK-Cu) have overlapping but non-identical mechanisms in tissue repair. Researchers designing preclinical protocols that evaluate multi-pathway regenerative signaling frequently want all three in parallel, and the fourth (KPV) adds an inflammation-modulation arm that the first three don’t cover well.
The following table summarizes the pathway-level rationale.
| Constituent | Mass in KLOW | Primary pathway (research context) | Key reference |
|---|---|---|---|
| BPC-157 | 10mg | Multi-pathway tissue repair (VEGF, NO, growth-factor receptor) | Sikiric et al., 2013 (PMID: 22950504) |
| TB-500 | 10mg | Actin sequestration, cell migration, angiogenesis | Goldstein et al., 2005 (PMID: 16110150) |
| GHK-Cu | 50mg | Copper delivery, extracellular matrix remodeling, broad gene expression modulation | Pickart & Margolina, 2015 (PMID: 26264936) |
| KPV | 10mg | Melanocortin signaling, NF-κB attenuation, anti-inflammatory research | Getting et al., 2003 (PMID: 12496404) |
What the table doesn’t fully capture is that these pathways are not fully independent in vivo. Inflammation and tissue repair interact tightly — a repair response that is not accompanied by resolution of inflammation tends to produce fibrosis rather than clean regeneration. That’s part of why researchers investigating combined-signaling protocols find the KPV addition mechanistically interesting.
Vitro Labs supplies two related proprietary blends: GLOW (70mg total: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg) and KLOW (80mg total: the GLOW composition plus 10mg of KPV).
The difference is exactly 10mg of KPV.
In research terms, that difference is more meaningful than the mass suggests. GLOW is a pure tissue-repair reference material — three compounds all studied primarily for regenerative and matrix-remodeling pathways. KLOW is a tissue-repair reference material that also carries the melanocortin-driven anti-inflammatory arm.
KLOW ships as a single lyophilized powder in an amber vial. All four compounds are freeze-dried together. The powder appearance and net content are verified per batch on the accompanying Certificate of Analysis.
In laboratory research protocols, lyophilized compound reference standards are typically reconstituted with bacteriostatic water or sterile water for laboratory use. The specific diluent, volume, and concentration chosen depend on the experimental design and are determined by the researcher and their institution’s protocols. Vitro Labs does not publish reconstitution protocols and does not provide dosing guidance — the material is a reference standard, not a formulation intended for administration.
The general research-laboratory storage profile for lyophilized compound reference standards is refrigerated (2-8°C) for shorter-term storage and frozen (-20°C or below) for longer-term storage, protected from light and moisture. Once reconstituted, compound stability decreases and cold storage is typical. Researchers should consult peer-reviewed stability literature for each constituent when planning experimental timelines.
Every batch of KLOW Blend is verified by Freedom Diagnostics, an ISO-certified independent analytical laboratory based in Franklin, Tennessee. The Certificate of Analysis reports identity (via LC-MS), purity (via HPLC-UV), net content, and appearance, along with the analytical methods used.
Because KLOW is a four-component blend, identity verification is more complex than for a single-compound reference material. The analytical workflow at Freedom Diagnostics confirms the presence and mass of each of the four constituents in the finished lyophilized product. Researchers evaluating batch documentation before adding KLOW to laboratory inventory can review the Certificate of Analysis for the specific lot they receive.
Vitro Labs supplies KLOW as an analytical-grade biochemical reference standard. The blend is available at the KLOW Blend product page for qualified research customers.
The individual constituent literatures continue to expand. Recent work on GHK-Cu has focused on the copper complex’s role in modulating extracellular matrix components in dermal fibroblast cultures, extending Pickart’s earlier gene-expression findings. Research on KPV has moved further into gut-inflammation models, building on the Kannengiesser 2008 paper.
What has not appeared in the peer-reviewed literature is a direct preclinical study of the KLOW four-compound combination as a single experimental unit. The combined-pathway framing is a research rationale drawn from the individual constituent literatures — not a claim that the specific KLOW composition has been characterized as a fixed mixture in peer-reviewed work. Researchers investigating the combined system are, in effect, adding to that literature themselves.
⚠️ Research Disclaimer: This article summarizes preclinical and in-vitro research on the constituent compounds of KLOW Blend. The article is provided for educational purposes and describes research findings in laboratory and animal models. KLOW Blend and its constituents are not approved for human consumption and are supplied strictly as analytical-grade reference standards for in-vitro research and laboratory evaluation by qualified research customers.
For the full editorial framework governing this article — sourcing standards, citation policy, review cycle — see Vitro’s Editorial Standards. For the broader compound reference library, see the Vitro Research Library.
KLOW Blend is an 80mg lyophilized reference standard containing four compounds in fixed masses: BPC-157 (10mg), TB-500 (10mg), GHK-Cu (50mg), and KPV (10mg). The composition is verified by Freedom Diagnostics on a batch-specific Certificate of Analysis. Identity is confirmed via LC-MS and purity via HPLC-UV for each constituent in the finished blend.
GLOW Blend (70mg) contains BPC-157, TB-500, and GHK-Cu — three compounds studied primarily for tissue-repair and matrix-remodeling pathways. KLOW Blend (80mg) is the GLOW composition plus 10mg of KPV, a 3-amino-acid compound fragment of alpha-MSH studied for anti-inflammatory signaling through the melanocortin receptor system. The KPV addition adds an inflammation-modulation arm to the repair-focused pathway profile of GLOW.
KPV is the C-terminal 3-amino-acid compound fragment of alpha-melanocyte-stimulating hormone. It engages the melanocortin receptor family and has been reported to attenuate NF-κB signaling and reduce downstream pro-inflammatory cytokine production in preclinical models. Getting and colleagues (2003, PMID: 12496404) characterized this activity in inflammatory cell models, and Kannengiesser and colleagues (2008, PMID: 18521914) extended it to gut inflammation models. The other three constituents of KLOW are studied primarily for tissue-repair and angiogenesis pathways rather than inflammation resolution.
The individual constituent compounds (BPC-157, TB-500, GHK-Cu, KPV) each have independent peer-reviewed research literatures spanning decades. The specific four-component KLOW blend has not been characterized as a single experimental unit in peer-reviewed publications; the combined-pathway framing is a research rationale drawn from the individual constituent literatures. Researchers investigating the combined system add to that literature through their own preclinical work.
KLOW Blend is supplied as a lyophilized powder in a single amber vial containing all four constituent compounds freeze-dried together. Every batch ships with a Certificate of Analysis from Freedom Diagnostics, an ISO-certified independent analytical laboratory in Franklin, Tennessee. The CoA reports identity via LC-MS, purity via HPLC-UV, net content, and appearance for the blend.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. KLOW Blend and its constituent compounds are research compounds not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for administration in humans or animals outside of approved research protocols. Products are supplied strictly for laboratory research use only.
